Insilico's AI-Driven Drug Rentosertib Shows Potential to Reverse Biological Age in Lung Disease
Insilico Medicine's AI-designed drug candidate Rentosertib has demonstrated potential in reversing biological aging in a lung disease model, according to assessments by six proteomic aging clocks.
Insilico Medicine has announced that its AI-developed drug candidate, Rentosertib, has shown promising results in the treatment of idiopathic pulmonary fibrosis (IPF). The drug was developed using the company's proprietary AI platforms, targeting both a novel target and designing the drug molecule itself.
The research findings, published in Nature Biotechnology, are based on the evaluation of six proteomic aging clocks. These clocks measure biological age based on protein changes. The study observed that Rentosertib could reverse biological aging, indicating its potential to not only slow but possibly improve the condition of IPF patients.
Rentosertib is the first-in-class drug designed entirely with generative AI. Its development involved AI models and assessments of the hallmarks of aging. The results represent the first universal consensus on using six proteomic aging clocks in drug development, potentially opening new avenues for research into age-related diseases.
Insilico's objective is to advance the clinical development of Rentosertib. The company has previously utilized its AI in research for other diseases, including cancer and fibrotic conditions. While the results are preliminary, they offer hope for treating intractable diseases like IPF.